Redeye leaves its comments on Ortoma following its Q2 2023 report. Ortoma has engaged the market launch in Japan for OTS™ Hip, and the report contained a milestone payment of SEK16.9m leading to a positive EBIT margin.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ortoma Q2 2023 - Ignition engaged

© Modular Finance, source Nordic Press Releases